RE-BVS – Piemonte Repository

Sfoglia per AUTORE
COLAFIGLI M
Collezione ASL Città di Torino

Items : 6

The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study. in Journal of acquired immune deficiency syndromes (1999) / J Acquir Immune Defic Syndr. 2019 May 1;81(1):e17-e21. doi: 10.1097/QAI.0000000000001986.

2019
ASL Città di Torino

Rossetti B; Gagliardini R; Sterrantino G; Colangeli V; Latini A; Colafigli M; Vignale F; Rusconi S; Di Biagio A; Orofino G; Mezzaroma I; Vullo V; Francisci D; Mastroianni C; Trezzi M; Canovari B; Lamonica S; Ciccullo A; Borghetti A; D?Arminio Monforte A; Di Giambenedetto S; De Luca A;

Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. in The Journal of antimicrobial chemotherapy / J Antimicrob Chemother. 2018 Jul 1;73(7):1955-1964. doi: 10.1093/jac/dky123.

2018
ASL Città di Torino

Fabbiani M; Gagliardini R; Ciccarelli N; Quiros Roldan E; Latini A; d'Ettorre G; Antinori A; Castagna A; Orofino G; Francisci D; Chinello P; Madeddu G; Grima P; Rusconi S; Del Pin B; Lombardi F; D'Avino A; Focà E; Colafigli M; Cauda R; Di Giambenedetto S; De Luca A;

Treatment simplification to atazanavir/ritonavir?+?lamivudine versus maintenance of atazanavir/ritonavir?+?two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). in The Journal of antimicrobial chemotherapy / J Antimicrob Chemother. 2017 Apr 1;72(4):1163-1171. doi: 10.1093/jac/dkw557.

2017
ASL Città di Torino

Di Giambenedetto S; Fabbiani M; Quiros Roldan E; Latini A; D'Ettorre G; Antinori A; Castagna A; Orofino G; Francisci D; Chinello P; Madeddu G; Grima P; Rusconi S; Di Pietro M; Mondi A; Ciccarelli N; Borghetti A; Focà E; Colafigli M; De Luca A; Cauda R;

Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial. in PloS one / PLoS One. 2017 Nov 21;12(11):e0187393. doi: 10.1371/journal.pone.0187393. eCollection 2017.

2017
ASL Città di Torino

Rossetti B; Gagliardini R; Meini G; Sterrantino G; Colangeli V; Re MC; Latini A; Colafigli M; Vignale F; Rusconi S; Micheli V; Di Biagio A; Orofino G; Ghisetti V; Fantauzzi A; Vullo V; Grima P; Francisci D; Mastroianni C; Antinori A; Trezzi M; Lisi L; Navarra P; Canovari B; D'Arminio Monforte A; Lamonica S; D'Avino A; Zazzi M; Di Giambenedetto S; et alii...

Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study. in Journal of the International AIDS Society / J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19818. doi: 10.7448/IAS.17.4.19818. eCollection 2014.

2014
ASL Città di Torino

Gagliardini R; Rossetti B; Bianco C; Rusconi S; Colafigli M; Prinapori R; Francisci D; Fantauzzi A; Orofino G; Vignale F; Di Giambenedetto S; De Luca A;

Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial. in Journal of the International AIDS Society / J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19808. doi: 10.7448/IAS.17.4.19808. eCollection 2014.

2014
ASL Città di Torino

Fabbiani M; Di Giambenedetto S; Quiros-Roldan E; Latini A; Vullo V; Antinori A; Castagna A; Orofino G; Francisci D; Grilli E; Madeddu G; Grima P; Rusconi S; Del Pin B; Mondi A; Borghetti A; Focà E; Colafigli M; De Luca A; Cauda R;